Analyst Price Targets — BDTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 16, 2026 11:54 am | Kelsey Goodwin | Piper Sandler | $8.00 | $2.67 | TheFly | Black Diamond Therapeutics price target lowered to $8 from $9 at Piper Sandler |
| October 15, 2025 8:31 pm | Laura Prendergast | Stifel Nicolaus | $8.00 | $4.14 | TheFly | Black Diamond Therapeutics resumed with a Buy at Stifel |
| September 3, 2025 8:15 pm | Brad Canino | Guggenheim | $8.00 | $2.88 | TheFly | Black Diamond Therapeutics initiated with a Buy at Guggenheim |
| July 31, 2024 8:18 am | Laura Prendergast | Raymond James | $20.00 | $5.91 | TheFly | Black Diamond Therapeutics initiated with an Outperform at Raymond James |
| June 3, 2024 8:52 am | Joseph Calanzaro | Piper Sandler | $12.00 | $4.78 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Black Diamond Therapeutics (BDTX) |
| May 16, 2024 6:12 am | Robert Burns | H.C. Wainwright | $11.00 | $5.44 | TheFly | Black Diamond price target lowered to $11 from $12 at H.C. Wainwright |
| April 8, 2024 7:07 am | Robert Driscoll | Wedbush | $16.00 | $5.06 | StreetInsider | Black Diamond Therapeutics (BDTX) PT Raised to $16 at Wedbush |
| March 18, 2024 6:38 am | Raghuram Selvaraju | H.C. Wainwright | $12.00 | $4.70 | StreetInsider | Black Diamond Therapeutics (BDTX) PT Raised to $12 at H.C. Wainwright |
Latest News for BDTX
Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock?
BDTX spotlights silevertinib's 86% CNS response in NSCLC, with 2026 durability data and a glioblastoma push shaping its brain-metastasis strategy.
BDTX hinges on silevertinib's mutation breadth and CNS activity, with 2026 data, cash runway, and partnership moves set to shape its high-risk, high-reward path.
BDTX bets on silevertinib's broad EGFR mutation reach and CNS activity, but with no approved products, upcoming 2026 data and partnerships are pivotal.
Black Diamond Therapeutics (BDTX) remains a 'Buy', as silevertinib shows promising efficacy in EGFR-mutant NSCLC with notable CNS activity. BDTX reported a 60% objective response rate and 86% CNS response rate in phase 2 silevertinib data, addressing key resistance mutations. Cash position supports operations into 2028, allowing BDTX to reach pivotal clinical catalysts before requiring additional funding.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BDTX.
U.S. House Trading
No House trades found for BDTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.